



Contacts: Tularik Inc.
Alicia Williams (Investors/Media), 650-825-7322

Tularik to Present at the SG Cowen Securities 24th Annual Healthcare Conference

South San Francisco, Calif. --(Business Wire) – March 5, 2004-- Tularik Inc. (Nasdaq:TLRK) announced today that Andrew Perlman, M.D., Ph.D., Executive Vice President, will present at the SG Cowen Securities 24th Annual Healthcare Conference on Tuesday, March 9, 2004 at 10:15 a.m. and 11:15 a.m. Eastern Time at the Boston Marriott Copley Place in Boston, Massachusetts.

The presentations will be webcast and may be accessed at the Company's website, www.tularik.com, under the Investors/Media tab. In addition, an archived version of the webcast will be available on the Company's website for 30 days.

About Tularik

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. The Company's scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. Tularik is currently conducting a pivotal study of T67 for the treatment of hepatocellular carcinoma (HCC) and Phase 2 clinical trials of T607 for the treatment of gastric cancer and esophageal cancer. T487, for the treatment of psoriasis, and T131, for the treatment of type 2 diabetes, are in Phase 2 clinical trials. T487 for the treatment of rheumatoid arthritis is moving into Phase 2 clinical trials. T71 for the treatment of obesity is in Phase 1 clinical trials. A corporate partner, Eli Lilly and Company, is conducting a Phase 2 clinical trial of an oral Factor Xa inhibitor for the prevention and treatment of thrombotic diseases. For more information, visit Tularik's Internet website at www.tularik.com.